Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 10/20 | 0.36 |
| ▸ | GLP1R | P43220 | 2/20 | 0.34 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 3/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1260127 | 0.82 | KMT2A (0.51) | ACSS2SMN1; SMN2 | |
| SCHEMBL1258368 | 0.78 | ACSS2 (0.36) | ACSS2BRD4CCNT1CDK9SMN1; SMN2 | |
| SCHEMBL1259848 | 0.77 | PRSS12 (0.32) | ACSS2PRSS12CCNT1CDK9SMN1; SMN2 | |
| SCHEMBL1260329 | 0.76 | ACSS2 (0.41) | ACSS2KDM4ELMNA | |
| SCHEMBL1260163 | 0.73 | AR (0.42) | ACSS2SMN1; SMN2KDM4ELMNA | |
| SCHEMBL1260310 | 0.72 | ACSS2 (0.38) | ACSS2SMN1; SMN2KDM4ELMNA | |
| SCHEMBL12712258 | 0.71 | KDM4E (0.36) | ACSS2KDM4ELMNA | |
| SCHEMBL1259198 | 0.68 | GAA (0.39) | ACSS2PRSS12LMNA | |
| SCHEMBL1260398 | 0.68 | ACSS2 (0.41) | ACSS2SMN1; SMN2KDM4ELMNA | |
| SCHEMBL1260363 | 0.66 | KMT2A (0.53) | ACSS2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812406-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2018-09-12 | — | — | EP | disclosed |
| EP-1805147-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-13 | — | — | EP | disclosed |
| EP-1805147-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-13 | — | — | EP | disclosed |
| US-8586616-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2013-11-19 | — | — | US | disclosed |
| US-8586616-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA, NV (BE) | 2013-11-19 | — | — | US | disclosed |
| US-20110086883-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | NG RAYMOND | 2011-04-14 | — | — | US | disclosed |
| US-20110086883-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | NG RAYMOND | 2011-04-14 | — | — | US | disclosed |
| US-20110086883-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | NG RAYMOND | 2011-04-14 | — | — | US | disclosed |
| US-7879895-B2 | prepared by mixing 1-(5,6-dichloro-1H-benzimidazol-2-yl)-2,2,2-trifluoro-ethanol with a carrier; non-steroidal agonists and antagonists; anticarcinogenic agents prostates; alopecia; eating disorders; acne; AIDS; cachexia | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-01 | — | — | US | disclosed |
| US-7879895-B2 | prepared by mixing 1-(5,6-dichloro-1H-benzimidazol-2-yl)-2,2,2-trifluoro-ethanol with a carrier; non-steroidal agonists and antagonists; anticarcinogenic agents prostates; alopecia; eating disorders; acne; AIDS; cachexia | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-01 | — | — | US | disclosed |
| US-20080119522-A1 | 5,6-dichloro-2-(2,2,2-trifluoro-ethyl)-1H-benzimidazole for example; use for prostate cancer, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive, and/or as a male performance enhancer | NG RAYMOND | 2008-05-22 | — | — | US | disclosed |
| US-7348438-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-25 | — | — | US | disclosed |
| US-7348438-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-25 | — | — | US | disclosed |
| US-7348438-B2 | Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-25 | — | — | US | disclosed |
| EP-1812406-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-01 | — | — | EP | disclosed |
| EP-1805147-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-11 | — | — | EP | disclosed |
| US-20060116412-A1 | Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| US-20060111402-A1 | Novel benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-25 | — | — | US | disclosed |
| WO-2006039215-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006039243-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086883-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) | AR, NR5A1, ESRRA | ACSS2 396/4885GLP1R 953/4885PRSS12 3344/4885 |
| US-20060111402-A1 | Novel benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) | AR, NR5A1, ESRRA | ACSS2 396/4885GLP1R 953/4885PRSS12 3344/4885 |
| US-20080119522-A1 | 5,6-dichloro-2-(2,2,2-trifluoro-ethyl)-1H-benzimidazole for example; use for prostate cancer, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive, and/or as a male performance enhancer | AR, FSHR, BRDT | ACSS2 640/4885GLP1R 1797/4885PRSS12 2352/4885 |
| US-20060116412-A1 | Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) | AR, NR5A1, ESRRA | ACSS2 396/4885GLP1R 953/4885PRSS12 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.